Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Casopitant + Ondansetron for PONV Prevention
NCT00274690Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2005
- Primary completion
- Aug 2005
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of casopitant in postoperative nausea and vomiting (PONV) (3 arms), sponsored by GSK. Primary endpoint: Proportion of subjects who achieve a complete response at 72 hours. Started Feb 2005; status: completed.
02
Drugs
casopitant
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT00274690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00274690.